Articles related to IMMUNOTHERAPY

Recent advances in CAR T-cell therapy show significant promise in treating both blood cancers and solid tumors, offering durable responses and extended survival rates for patients previously facing limited options.

ESMO Congress 2023 unveils groundbreaking advances in mUC treatments, emphasizing novel therapeutic combinations and the critical role of personalized medicine in improving patient outcomes.

In a recent study, researchers found that, although pembrolizumab increased the pathological complete response in gastric cancer patients, it did not significantly improve event-free survival.

At ECTRIMS-ACTRIMS 2023, pivotal studies like the OLIKOS and MIRANTIBUS trials have highlighted the evolving dynamics in MS treatment, particularly emphasizing the shift towards more patient-centric and effective therapeutic approaches.

An in-depth look at the FDA’s clinical hold on Iovance’s lung cancer cell therapy trial reveals crucial insights into the safety and progression of innovative cancer treatments.

The bispecific antibody targets both CD20 and CD3 proteins and has demonstrated the capacity of activated immune cells to eliminate lymphoma cells, achieving deep and potentially curable remissions.